These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 6084143)

  • 1. Pathophysiologic mechanisms in essential hypertension: a clue to the therapeutic approach.
    Messerli FH
    J Cardiovasc Pharmacol; 1984; 6 Suppl 6():S875-9. PubMed ID: 6084143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of diuretic agents in obese or black patients with systemic hypertension.
    Messerli FH; Schmieder RE
    Am J Cardiol; 1986 Jul; 58(2):11A-14A. PubMed ID: 3728340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemodynamic and cardiac adaptation in essential hypertension. Consequences for therapy.
    Messerli FH
    J Clin Hypertens; 1985 Mar; 1(1):3-14. PubMed ID: 2425059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Essential hypertension. Matching pathophysiology and pharmacology.
    Messerli FH
    Postgrad Med; 1987 Feb; 81(2):165-72, 179-80. PubMed ID: 3543906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular pathophysiology of essential hypertension: a clue to therapy.
    Messerli FH; Ventura HO
    Drugs; 1985; 30 Suppl 1():25-34. PubMed ID: 2994985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disparate cardiovascular effects of obesity and arterial hypertension.
    Messerli FH; Sundgaard-Riise K; Reisin E; Dreslinski G; Dunn FG; Frohlich E
    Am J Med; 1983 May; 74(5):808-12. PubMed ID: 6340494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular adaptation to obesity and hypertension.
    Lavie CJ; Messerli FH
    Chest; 1986 Aug; 90(2):275-9. PubMed ID: 2942341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obesity hypertension. Converting enzyme inhibitors and calcium antagonists.
    Frohlich ED
    Hypertension; 1992 Jan; 19(1 Suppl):I119-23. PubMed ID: 1730448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion, and plasma renin activity.
    Messerli FH; Christie B; DeCarvalho JG; Aristimuno GG; Suarez DH; Dreslinski GR; Frohlich ED
    Arch Intern Med; 1981 Jan; 141(1):81-5. PubMed ID: 7004372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does obesity influence early target organ damage in hypertensive patients?
    Schmieder RE; Messerli FH
    Circulation; 1993 May; 87(5):1482-8. PubMed ID: 8491003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation of various degrees of body mass index in patients with systemic hypertension to left ventricular mass, cardiac output, and peripheral resistance (The Hypertension Genetic Epidemiology Network Study).
    Palmieri V; de Simone G; Arnett DK; Bella JN; Kitzman DW; Oberman A; Hopkins PN; Province MA; Devereux RB
    Am J Cardiol; 2001 Nov; 88(10):1163-8. PubMed ID: 11703964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular effects of obesity and hypertension.
    Messerli FH
    Lancet; 1982 May; 1(8282):1165-8. PubMed ID: 6122945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of left ventricular hypertrophy in essential hypertension: should echocardiography guide the pharmacological treatment?
    Dávila DF; Donis JH; Odreman R; Gonzalez M; Landaeta A
    Int J Cardiol; 2008 Feb; 124(2):134-8. PubMed ID: 17467083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathophysiologic clinical clues in essential hypertension: a rationale for initial therapy.
    Messerli FH
    J Cardiovasc Pharmacol; 1984; 6 Suppl 3():S528-34. PubMed ID: 6208423
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardiodynamics of hypertension: a guide to selection of therapy.
    Messerli FH; Garavaglia GE
    J Clin Hypertens; 1986 Sep; 2(3 Suppl):100S-108S. PubMed ID: 3540221
    [No Abstract]   [Full Text] [Related]  

  • 16. Obesity and hypertension.
    Schmieder RE; Rockstroh JK
    Curr Opin Nephrol Hypertens; 1994 Sep; 3(5):546-9. PubMed ID: 7804753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertension in black patients. Epidemiologic and pathophysiologic considerations.
    Wallin JD
    J Clin Hypertens; 1986 Mar; 2(1):7-12. PubMed ID: 3522816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic role of extracellular fluid in hypertension.
    Tarazi RC
    Circ Res; 1976 Jun; 38(6 Suppl 2):73-83. PubMed ID: 773571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic management of systemic hypertension in blacks.
    Weir MR; Saunders E
    Am J Cardiol; 1988 Jun; 61(16):46H-52H. PubMed ID: 3289351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydralazine as antihypertensive therapy in obesity-related hypertension.
    Carroll JF; King JW; Cohen JS
    Int J Obes Relat Metab Disord; 2004 Mar; 28(3):384-90. PubMed ID: 14767494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.